Cargando…

First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study

OBJECTIVE: Gestational diabetes mellitus (GDM) is associated with excessive fetal growth in later gestation. Recent data suggest accelerated growth may begin before 28 weeks' gestation when GDM is typically diagnosed. The identification of pregnancies at risk of early fetal growth would enable...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Arcy, Robert J., Cooke, Inez E., McKinley, Michelle, McCance, David R., Graham, Una M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107539/
https://www.ncbi.nlm.nih.gov/pubmed/36453695
http://dx.doi.org/10.1111/dme.15019
_version_ 1785026627336404992
author D'Arcy, Robert J.
Cooke, Inez E.
McKinley, Michelle
McCance, David R.
Graham, Una M.
author_facet D'Arcy, Robert J.
Cooke, Inez E.
McKinley, Michelle
McCance, David R.
Graham, Una M.
author_sort D'Arcy, Robert J.
collection PubMed
description OBJECTIVE: Gestational diabetes mellitus (GDM) is associated with excessive fetal growth in later gestation. Recent data suggest accelerated growth may begin before 28 weeks' gestation when GDM is typically diagnosed. The identification of pregnancies at risk of early fetal growth would enable early intervention. We assessed the use of early pregnancy HbA1c in predicting excessive fetal growth. RESEARCH DESIGN AND METHODS: Women were recruited at antenatal booking from a major maternity unit in the UK. HbA1c was measured at <14 weeks gestation in 1243 women at risk of GDM as defined by UK NICE risk factors of whom 1115 underwent OGTT. Women with previous GDM were excluded. Comprehensive fetal ultrasound was performed at 28 weeks' gestation alongside 75 g OGTT in 976 of these women. GDM was defined using WHO criteria. Pregnancy outcomes were extracted from the regional maternity care database. RESULTS: Two hundred and thirty‐six women screened positive for GDM. At diagnosis, GDM pregnancies demonstrated higher adjusted fetal weight percentile than non‐GDM pregnancies: (51.8 vs. 46.3, p = 0.008). This was driven by increases in the fetal abdominal circumference percentile in GDM compared with non‐GDM pregnancies (55.3 vs. 46.2, p = <0.001). Early pregnancy HbA1c was higher in the GDM versus non‐GDM group: (35.7 mmol/mol vs. 32.9 mmol/mol p = <0.01). A threshold for predicting excessive fetal growth was not identified in this cohort. CONCLUSIONS: Accelerated fetal growth is evident prior to the diagnosis of GDM. There remains a need for suitable methods of early identification of pregnancies at high risk for early accelerated fetal growth due to GDM. First‐trimester HbA1c was not useful in identifying these pregnancies. NOVELTY STATEMENT: WHAT IS ALREADY KNOWN? Recent research suggests excessive growth associated with GDM may begin prior to 28 weeks' gestation, when GDM is typically tested for. WHAT THIS STUDY HAS FOUND? Pregnancies affected by GDM are already subject to accelerated fetal growth in comparison to non‐GDM pregnancies by way of higher estimated fetal weight and fetal abdominal circumference. Neither first‐trimester HbA1c nor plasma glucose was useful predictors of these outcomes. WHAT ARE THE IMPLICATIONS OF THIS STUDY? Highlights the emergence of excessive growth prior to detection of GDM: Reinforces need for suitable methods of identifying such pregnancies in earlier gestation;
format Online
Article
Text
id pubmed-10107539
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101075392023-04-18 First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study D'Arcy, Robert J. Cooke, Inez E. McKinley, Michelle McCance, David R. Graham, Una M. Diabet Med Research: Pathophysiology OBJECTIVE: Gestational diabetes mellitus (GDM) is associated with excessive fetal growth in later gestation. Recent data suggest accelerated growth may begin before 28 weeks' gestation when GDM is typically diagnosed. The identification of pregnancies at risk of early fetal growth would enable early intervention. We assessed the use of early pregnancy HbA1c in predicting excessive fetal growth. RESEARCH DESIGN AND METHODS: Women were recruited at antenatal booking from a major maternity unit in the UK. HbA1c was measured at <14 weeks gestation in 1243 women at risk of GDM as defined by UK NICE risk factors of whom 1115 underwent OGTT. Women with previous GDM were excluded. Comprehensive fetal ultrasound was performed at 28 weeks' gestation alongside 75 g OGTT in 976 of these women. GDM was defined using WHO criteria. Pregnancy outcomes were extracted from the regional maternity care database. RESULTS: Two hundred and thirty‐six women screened positive for GDM. At diagnosis, GDM pregnancies demonstrated higher adjusted fetal weight percentile than non‐GDM pregnancies: (51.8 vs. 46.3, p = 0.008). This was driven by increases in the fetal abdominal circumference percentile in GDM compared with non‐GDM pregnancies (55.3 vs. 46.2, p = <0.001). Early pregnancy HbA1c was higher in the GDM versus non‐GDM group: (35.7 mmol/mol vs. 32.9 mmol/mol p = <0.01). A threshold for predicting excessive fetal growth was not identified in this cohort. CONCLUSIONS: Accelerated fetal growth is evident prior to the diagnosis of GDM. There remains a need for suitable methods of early identification of pregnancies at high risk for early accelerated fetal growth due to GDM. First‐trimester HbA1c was not useful in identifying these pregnancies. NOVELTY STATEMENT: WHAT IS ALREADY KNOWN? Recent research suggests excessive growth associated with GDM may begin prior to 28 weeks' gestation, when GDM is typically tested for. WHAT THIS STUDY HAS FOUND? Pregnancies affected by GDM are already subject to accelerated fetal growth in comparison to non‐GDM pregnancies by way of higher estimated fetal weight and fetal abdominal circumference. Neither first‐trimester HbA1c nor plasma glucose was useful predictors of these outcomes. WHAT ARE THE IMPLICATIONS OF THIS STUDY? Highlights the emergence of excessive growth prior to detection of GDM: Reinforces need for suitable methods of identifying such pregnancies in earlier gestation; John Wiley and Sons Inc. 2022-12-12 2023-02 /pmc/articles/PMC10107539/ /pubmed/36453695 http://dx.doi.org/10.1111/dme.15019 Text en © 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research: Pathophysiology
D'Arcy, Robert J.
Cooke, Inez E.
McKinley, Michelle
McCance, David R.
Graham, Una M.
First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title_full First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title_fullStr First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title_full_unstemmed First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title_short First‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: A prospective cohort study
title_sort first‐trimester glycaemic markers as predictors of gestational diabetes and its associated adverse outcomes: a prospective cohort study
topic Research: Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107539/
https://www.ncbi.nlm.nih.gov/pubmed/36453695
http://dx.doi.org/10.1111/dme.15019
work_keys_str_mv AT darcyrobertj firsttrimesterglycaemicmarkersaspredictorsofgestationaldiabetesanditsassociatedadverseoutcomesaprospectivecohortstudy
AT cookeineze firsttrimesterglycaemicmarkersaspredictorsofgestationaldiabetesanditsassociatedadverseoutcomesaprospectivecohortstudy
AT mckinleymichelle firsttrimesterglycaemicmarkersaspredictorsofgestationaldiabetesanditsassociatedadverseoutcomesaprospectivecohortstudy
AT mccancedavidr firsttrimesterglycaemicmarkersaspredictorsofgestationaldiabetesanditsassociatedadverseoutcomesaprospectivecohortstudy
AT grahamunam firsttrimesterglycaemicmarkersaspredictorsofgestationaldiabetesanditsassociatedadverseoutcomesaprospectivecohortstudy